Salute e Benessere

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – August 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on August 6, 2025, from Atlas Special…
Actusnews Wire
06/08/2025

Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest…

Get a Free Sample Copy of the Report: https://www.skyquestt.com/sample-request/biomarkers-market Get a Free Sample Copy of the Report:https://www.skyquestt.com/sample-request/biomarkers-market Biomarkers Market Key Growth Drivers The biomarkers market is experiencing strong growth, driven by the rising demand for personalized medicine, where biomarkers play a key role in tailoring treatments based on individual genetic and molecular profiles. Increasing prevalence of chronic diseases...
PR Newswire
06/08/2025

Biopharmaceutical CDMO Market worth US$34.15 billion in 2030 with 8.8% CAGR |…

Browse in-depth TOC on "Biopharmaceutical CDMO Market" Browse in-depth TOC on "Biopharmaceutical CDMO Market" 422 - Tables 57 - Figures 380 - Pages By Service,the global biopharmaceutical contract manufacturing market is divided into four main service categories: manufacturing, formulation & fill-finish, packaging & labeling, and other services. The formulation & fill-finish segment accounts for the second-largest share of the market due to the rising demand…
PR Newswire
06/08/2025

Pharmaceutical Suppositories Market is expected to generate a revenue of USD…

The global Pharmaceutical Suppositories Market is expanding as healthcare providers seek effective, localized, and non-invasive drug delivery methods. Rising chronic diseases and pediatric/geriatric care needs are propelling demand across developed and emerging economies. The global Pharmaceutical Suppositories Market is expanding as healthcare providers seek effective, localized, and non-invasive drug delivery methods. Rising chronic diseases and pediatric/geriatric care needs are propelling...
PR Newswire
06/08/2025

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum…

Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes (the “Facility”), subject to the satisfaction or waiver of certain conditions, to support the launch of its Ethereum (ETH) digital asset treasury reserve...
Nasdaq GlobeNewswire
06/08/2025

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for…

Click here to view the custom infographic of the Soligenix Inc. editorial. Clickhere to view the custom infographic of the Soligenix Inc. editorial. Chronic Conditions Demand Targeted Innovation Chronic rare diseases are becoming a major challenge for the aging population in the United States. As life expectancy rises, healthcare needs become more complex, especially for conditions that are long-lasting and hard to diagnose. With tens of millions of Americans living with a rare...
PR Newswire
06/08/2025

Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to…

Dr. Joseph M. DeSimone Dr.Joseph M. DeSimone Executive Commentary "We are honored to welcome Josephine and Joe to our Board," said Bob Whitehead , Co-Founder and Executive Chairman of Continuity Biosciences. "Josephine's regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs…
PR Newswire
06/08/2025

Alvotech Announces Webcast to Report Financial Results for the First Half of…

REYKJAVIK, ICELAND (August 6, 2025)– Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am...
Nasdaq GlobeNewswire
06/08/2025

Three-Day Longevity & Wellness Summit Set to Transform Health Innovation…

The summit will feature an impressive roster of international health and longevity experts, including: The summit will feature an impressive roster of international health and longevity experts, including: Additional speakers fromthe United States,United Kingdom, andMiddle Eastwill explore cutting-edge topics including biohacking and longevity, functional and precision medicine, nutritional science, AI-powered diagnostics, and emotional well-being optimization. In addition to...
PR Newswire
06/08/2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First…

FDA approves single-dose AJOVY ®(fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration 1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults 1 This...
Nasdaq GlobeNewswire
06/08/2025

Forte Medical National Survey Announcement

Urinary Tract Infection (UTI) and prenatal screening: why do c14.2m UK women still suffer with up to 30% inaccuracy, failed hygiene and dignity? UK based Medical Technology company Forte Medical is launching a national survey of women in the UK, to ascertain their exposure to urine sampling retests and immediate empirical broad spectrum prescribing, triggered by traditional methods of specimen collection for Urinary Tract Infection and prenatal screening. The survey is independently...
Nasdaq GlobeNewswire
06/08/2025

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce…

Targeting Feeding Challenges with Advanced Venting Technology Targeting Feeding Challenges with Advanced Venting Technology Colic and spit-up are common concerns for parents of newborns, whose digestive systems are still developing. To address this challenge, Thyseed's R&D team conducted thousands of simulations to develop the bottom vent design. During feeding, the bottle's internal pressure changes precisely control the vent's opening and closing, preventing air from mixing into milk...
PR Newswire
06/08/2025

Thyseed Is Set to Support Southeast Asian Families with Safer Infant Feeding…

Brand Commitment: Safety Built on Love Brand Commitment: Safety Built on Love Thyseed incorporates its Design From Love philosophy into every part of the brand experience. This love is shown in its strong focus on safety, believing that "every touchpoint matters in early development." Thyseed goes beyond global safety standards, using a full safety system from raw materials to finished products. All raw materials are checked for safety, production areas meet medical-grade…
PR Newswire
06/08/2025

Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant…

Bagsværd, Denmark, 6 August 2025-Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased by 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion.Sales in US Operations increased by 16% in Danish kroner (17% at CER). Sales in the US were positively impacted by...
Nasdaq GlobeNewswire
06/08/2025

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of…

Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.EINDHOVEN, The Netherlands, Aug.06, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX:...
Nasdaq GlobeNewswire
06/08/2025

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT)…

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL). The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review...
Nasdaq GlobeNewswire
06/08/2025

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.

Sanofi completes the acquisition of Vigil Neuroscience, Inc.Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc.(“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s...
Nasdaq GlobeNewswire
06/08/2025

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the…

HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure...
PR Newswire
06/08/2025

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline…

Key Takeaways from the TYK2 Inhibitors Market Report Key Takeaways from the TYK2 Inhibitors Market Report Discover which indication is expected to grab the major TYK2 inhibitors market share @TYK2 Inhibitors Market Report TYK2 Inhibitors Market Dynamics The market for TYK2 inhibitors is emerging as a dynamic and rapidly evolving segment within thebroader immunology and inflammation therapeutics space. Unlike broader JAK inhibitors that often target multiple JAK subtypes...
PR Newswire
05/08/2025

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates…

– Xywav® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Xywav® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Zepzelca® granted Priority Review in 1L ES-SCLC – DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2025 and updated financial guidance for 2025. "It has been a privilege to lead...
PR Newswire
05/08/2025

Press release: CMS Approves Additional Payment for Sequana Medical’s alfapump®…

CMS Approves Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Casesalfapump® New Technology Add-on Payment (NTAP) Included in CMS Final Fiscal Year 2026 Rule and in effect by October 1, 2025NTAP provides for up to $21,450 when performed in the hospital inpatient settingalfapump® US commercial launch remains on track for Q3 2025 through specialty commercial team focused on liver transplant centersGhent, Belgium – 5 August 2025 –...
Nasdaq GlobeNewswire
05/08/2025

VALNEVA Declaration of shares and voting rights: July 31, 2025

VALNEVADeclaration of shares and voting rightsJuly 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: August 5, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
05/08/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

Aggregatedpresentationbydayandbymarket Statement of transactions in own shares from July 28th to August 1 st2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
05/08/2025

Morphic Medical Announces CEO Transition

The Board of Directors is pleased to announce that Mike Gutteridge will assume the role of CEO, bringing with him a wealth of experience in the bariatric endoscopy space. Mike most recently served as Vice President of Therapy Development and Commercial Operations at Morphic where he developed the companies go-to-market strategy for RESET®. The Board of Directors is pleased to announce thatMike Gutteridgewill assume the role of CEO, bringing with him a wealth of experience in the bariatric...
PR Newswire
05/08/2025
Altri  Comunicati